With the enactment of the Affordable Care Act in 2010, pharmaceutical and medical device firms were required to report payments that they make to physicians to the federal government.1 Administered by the Centers for Medicare & Medicaid Services, the Open Payments program aggregates this payment information and makes it publicly available.2 To ensure accuracy, physicians can report errors in their reported payments during the Open Payments annual review and dispute period, and drug and device firms will work with physicians to correct any misreporting in the system.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Kanter GP, Loewenstein G. Evaluating Open Payments. JAMA. 2019;322(5):401–402. doi:10.1001/jama.2019.8171
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: